Biotech VC Funds

Amplitude Ventures is a Montreal-based venture capital firm, founded in 2018, that focuses on precision medicine, investing at the intersection of biology and AI. The firm aims to support and scale companies that drive significant advancements in healthcare, particularly within Canada's innovation-rich ecosystem. Notable investments include Zymeworks, a biopharmaceutical company specializing in protein therapeutics, which went public in 2017, and Milestone Pharmaceuticals, known for its treatment for cardiovascular conditions, which also went public in 2019. Other key investments are DrugBank, a comprehensive drug database, and Valence Labs, which was acquired by Recursion. Amplitude Ventures recently closed a $263 million fund, significantly enhancing their capacity to invest in and grow cutting-edge precision medicine companies. The firm operates with a hands-on approach, providing strategic guidance and leveraging a strong network of industry experts. The leadership team includes co-founders Dion Madsen, Jean-François Pariseau, and Bharat Srinivasa, who bring extensive experience in life sciences and venture capital, ensuring robust support for their portfolio companies.

Amplo, founded in 2017 and headquartered in Spring, Texas, is a global venture capital firm that invests in early-stage startups across various sectors, including financial technology, artificial intelligence, healthcare, and software. The firm has built an impressive portfolio with notable companies such as Robinhood, Parsley Health, and 1Concern. Amplo has successfully supported eight unicorns, including Genies, Ironclad, and TravelPerk, highlighting its strategic investment approach. The firm emphasizes backing companies that aim to create meaningful societal impact, reflecting its commitment to innovation and positive change. Recent investments include Crosby Health and Two Chairs, which focus on health tech and healthcare services, respectively. The team at Amplo is led by Sheel Tyle, the founder and CEO, and consists of experienced professionals dedicated to providing strategic support and resources to their portfolio companies.

Ananda Impact Ventures, established in 2009, is a leading European venture capital firm dedicated to impact investing. The firm operates primarily in the DACH region, the UK, Benelux, and Scandinavia, focusing on early-stage investments from Seed to Series A rounds. Ananda manages around €200 million in assets across multiple funds, including their latest €108 million fund launched in 2023. Ananda invests in companies that address significant social and environmental challenges, aligning their business models with the UN’s Sustainable Development Goals. Their portfolio includes companies like OroraTech, which uses satellite technology to monitor wildfires, and NatureMetrics, which provides biodiversity data solutions through eDNA technology. The firm's investment strategy is built on their unique Impact Termsheet, which ties financial success to measurable impact outcomes. This model ensures that the impact is integral to the business, fostering long-term sustainability and growth. Ananda also emphasizes diversity and founder health, supporting entrepreneurs with robust resources and a hands-on approach to partnership. Founders appreciate Ananda's supportive and mission-aligned investment approach, which combines financial backing with strategic guidance to help scale impactful innovations. The firm prides itself on its deep commitment to creating positive societal change through venture capital.

Andera Partners, established in 2001 and headquartered in Paris, is a prominent private equity firm specializing in investments in life sciences, growth capital, and buyouts. The firm has built a strong reputation for its expertise in supporting companies at various development stages, particularly within the biotech and medical technology sectors. One of Andera's flagship initiatives is the BioDiscovery fund family, which has collectively raised over €1.1 billion to date. Their latest fund, BioDiscovery 6, closed at €456 million, highlighting significant investor confidence. This fund targets innovative therapeutic products and medical technologies, investing in companies across Europe and the United States. Notable investments include companies like Evommune, Amolyt, and TargED. Andera Partners employs a hands-on approach, providing both financial and strategic support to its portfolio companies. The firm's life sciences team, comprising experienced professionals like Sofia Ioannidou, Olivier Litzka, and Gilles Nobécourt, plays a crucial role in guiding startups from the preclinical stages to commercialization. Their strategic partnerships and extensive network bolster their ability to support high-potential innovations.

Andreessen Horowitz (a16z), headquartered in Menlo Park, California, is a premier venture capital firm known for its significant impact on the tech industry. Founded in 2009 by Marc Andreessen and Ben Horowitz, the firm has invested in high-profile startups such as Facebook, Airbnb, GitHub, and Coinbase. Their portfolio boasts a diverse range of industries, including AI, biotech, fintech, and consumer tech. A16z has a unique approach to investing, combining capital with extensive support. Their investments range from seed to late-stage funding, with recent high-profile investments including Mistral AI and Pinecone. They actively support their portfolio companies through a robust ecosystem of resources, including a market development team, operating partners, and a talent network​​. The firm is also heavily involved in emerging technologies, particularly in the cryptocurrency and blockchain space. They have launched dedicated funds for crypto investments and established initiatives like the a16z Crypto School to educate and support founders in this domain. Furthermore, their Cultural Leadership Fund aims to enhance diversity and inclusion in the tech industry​​. For founders, a16z's focus on innovation and long-term support makes them an attractive partner. They value visionary, dedicated founders and look for startups with significant market potential and disruptive capabilities. This holistic support strategy sets a16z apart, offering more than just financial investment but also strategic guidance and network access to help startups thrive.

Angeleno Group, founded in 2001 and based in Los Angeles, is a venture capital firm specializing in growth capital for next-generation clean energy and climate solutions companies. With a strategic focus on sectors such as renewable energy, energy storage, sustainable mobility, and carbon mitigation, Angeleno Group aims to address critical global challenges posed by climate change. The firm leverages its extensive industry experience and longstanding relationships to support high-growth, innovative businesses. Angeleno Group invests opportunistically, typically deploying between $10 million and $30 million per opportunity, and focuses on companies with proven technologies and established customer traction. Their portfolio includes a diverse array of companies such as Fictiv, Span, and Anza RE, highlighting their commitment to fostering sustainable and transformative technologies. Angeleno Group's investment strategy is deeply rooted in creating value through active engagement with portfolio companies, providing support in product development, business strategy, sales, and corporate finance. The firm's approach is sector-focused, research-driven, and designed to build a diversified and high-return portfolio.

Angelini Ventures is the corporate venture capital arm of Angelini Industries, founded in 2021 and headquartered in Rome, Italy. With a capital commitment of €300 million, Angelini Ventures focuses on early-stage investments in biotechnology, digital health, and life sciences. The firm aims to leverage technology to improve healthcare, reshape patient journeys, and address unmet needs in vulnerable populations. The firm has made significant investments globally, including in Europe, North America, and Israel, with a particular emphasis on brain health and consumer segments such as women, children, and the elderly. Notable portfolio companies include Pretzel Therapeutics, Argobio, Serenis, and Nouscom. Angelini Ventures is led by CEO Paolo Di Giorgio, who has extensive experience in the pharmaceutical and investment sectors. The team includes experts such as Elia Stupka, Managing Director, and Gabriela Manrique, Partner, among others, spread across major innovation hubs globally​.

Angels Santé, established in 2008 and based in Paris, is the largest healthcare-focused business angel network in Europe. It supports early-stage startups in the Biotech, Medtech, and Digital Health sectors, helping bring innovative solutions to market that benefit patients. With over 100 investments made since its inception, the organization fosters partnerships between entrepreneurs and healthcare professionals, providing not only capital but also deep industry expertise in clinical, regulatory, and scientific domains. Each year, Angels Santé finances 10-15 deals, with a focus on Europe, but its reach extends globally through partnerships with organizations like EBAN and Business Angels Europe. This international collaboration allows Angels Santé to facilitate cross-border investments and provide startups with access to a broader market. The network emphasizes a hands-on approach, guiding startups through the complexities of the healthcare landscape by offering mentorship and connections to relevant stakeholders. Notable figures such as Eric Garnier, the president, emphasize the critical role that healthcare innovation plays in solving modern challenges. Furthermore, their US branch, based in Boston, extends opportunities for French-speaking investors in the United States to support healthcare startups with global aspirations. Angels Santé is not just about funding; it's about building a community dedicated to advancing healthcare through innovation, with a long-term commitment to improving patient outcomes and supporting the growth of impactful healthcare companies.

Animal Capital, founded in 2020 and based in New York, is a venture capital firm that focuses on investments in consumer technology, financial technology, health and wellness, and media sectors. This firm is distinguished by its unique approach, leveraging the influence of its founders, who are prominent social media stars such as Josh Richards, Griffin Johnson, and Noah Beck, to drive consumer awareness and engagement for its portfolio companies. Notable investments by Animal Capital include Breakr, a platform connecting artists with influencers; Step, a banking app aimed at helping teenagers build credit and learn financial literacy; and Super Coffee, a sugar-free, enhanced coffee brand. Other significant investments include Colossal Laboratories & Biosciences, which focuses on biotechnology, and Zurp, a social platform software company. Animal Capital's strategy involves providing traditional venture capital services such as fundraising and scaling companies, alongside leveraging the founders' broad networks and influence to impact consumer purchasing decisions. This Gen Z-focused approach aims to set new standards in the investment space by effectively tapping into the purchasing power and cultural influence of younger generations.

Ankur Capital is an early-stage venture capital firm based in India, specializing in transformative technologies targeting the next billion people. Founded with a mission to support innovative business models addressing core challenges in sectors such as agriculture, healthcare, education, and fintech, Ankur Capital invests in both digital technology and deep science technology-led companies. Their portfolio includes companies like Cropin, which is driving smart farming; Niramai, pioneering early breast cancer detection with AI; and StringBio, which converts greenhouse gases into value-added proteins. Ankur Capital is dedicated to creating impact through responsible agriculture, climate mitigation and adaptation, and inclusive growth. The firm emphasizes hands-on support, working closely with entrepreneurs from seed to scale. Through their in-house platform, AnkurGro, they provide strategic guidance and operational assistance to help founders navigate their growth journey.

Anorak Ventures, founded in 2016 and headquartered in San Francisco, is a seed-stage venture firm that focuses on investing in transformative technology and people. The firm primarily invests in pre-seed and seed-stage companies across various technology sectors, including artificial intelligence and machine learning (AI/ML), Internet of Things (IoT), robotics, and consumer tech. Anorak Ventures has invested in over 120 seed-stage technology companies, which now represent an aggregate market capitalization of $24.8 billion. Notable investments in their portfolio include companies such as Vantage Point, WeatherCheck, Orderful, Framework, Prisms VR, Better Health, and Marxent. They are dedicated to helping these companies achieve product-market fit and secure follow-on financing. The firm, led by Managing Partner Greg Castle, aims to support innovative startups by providing not just capital but also strategic guidance to help them scale and succeed in competitive markets​.

ANRI is a venture capital firm based in Tokyo, Japan, focusing primarily on seed and early-stage investments. Founded with the mission to drive innovation, ANRI has invested in over 260 companies, emphasizing sectors such as electric vehicles, recycling, manufacturing, and information technology. Notable investments by ANRI include startups like Turing, a manufacturer in the electric vehicle sector, and amu, which focuses on recycling and waste management. Their portfolio showcases a strong commitment to diverse industries, including health tech and fintech. ANRI's investment approach often involves co-investing with other significant players in the market, thereby enhancing their portfolio companies' growth and market reach. ANRI has successfully achieved exits with companies like Raksul, DELY, and Coincheck, highlighting their capability to nurture startups towards profitable outcomes. Their investment philosophy emphasizes supporting innovative ideas that have the potential to make substantial impacts globally. The firm is also committed to diversity and inclusion, having set and achieved goals to increase investments in startups led by women. This dedication to fostering a diverse entrepreneurial ecosystem is part of ANRI's broader strategy to drive meaningful change and innovation in the startup landscape​.

Anterra Capital is a venture capital firm that specializes in investments within the food and agricultural technology sectors. Founded in 2013, Anterra Capital has offices in Amsterdam and Boston and focuses on backing innovative companies that address critical challenges in agriculture, food production, and sustainability. Their portfolio includes notable investments such as Enko Chem, which develops novel crop protection products; ProducePay, a financial and data services platform for the fresh produce industry; and BiomEdit, which focuses on microbiome innovation for animal health. The firm manages over $450 million in assets and typically invests in Series A or B rounds, with initial checks ranging from $1 to $10 million. Anterra is committed to leveraging biotechnology and digital solutions to transform the food system, improve consumer health, and enhance the livelihoods of farmers. Their investment strategy emphasizes impact and sustainability, aligning with their goal to create a resilient and sustainable food system. Anterra Capital has raised significant funds, including a $260 million second Global Food and Agriculture Technology Fund, which continues to support biotech and digital innovations in the agrifood sector​.

Anthemis Group, founded in 2010 and headquartered in London, is a global investment platform dedicated to fostering innovation in the financial system. The firm focuses on fintech, insurtech, and related sectors, investing from seed to growth stages. Anthemis' portfolio includes notable companies such as Betterment, eToro, and Currencycloud. They also back innovative startups like Pipe, Weavr, and Atomic. With over 150 investments worldwide, Anthemis emphasizes diversity and inclusivity, with 23% of their portfolio companies founded by women and 40% led by women or BIPOC. Their commitment to diversity is further demonstrated through the Female Innovators Lab, which supports female founders in fintech across the UK and Europe. Anthemis recently closed multiple funds totaling over $700 million, expanding their support for fintech companies throughout their lifecycle. The firm also launched an ESG-focused SPAC to advance sustainable finance. Anthemis' thesis-driven approach leverages deep market insights to drive systemic, long-term change. Led by founder Amy Nauiokas and CEO Briana van Strijp, Anthemis is poised to continue its mission of reinventing finance through innovation, collaboration, and inclusivity, supporting the next wave of fintech innovation globally.

Anthos Capital, founded in 2007 and based in Santa Monica, California, focuses on growth-stage investments in consumer products, technology, healthcare, and financial services sectors. The firm has made notable investments in companies like Carbon Robotics, known for its Autonomous Weeder which helps reduce reliance on herbicides, and Todyl, a comprehensive cybersecurity platform aimed at small and mid-market businesses. Anthos Capital takes a strategic partnership approach, providing not just capital but also operational and strategic support to help portfolio companies grow and lead their industries. They focus on investments that promise significant growth and impact, supporting companies from early to growth stages with tailored assistance. The firm's recent investment activities include significant funding rounds for companies like Carbon Robotics and Todyl, reflecting their commitment to fostering innovation and industry leadership. Their portfolio showcases a diverse range of companies, emphasizing Anthos Capital's ability to identify and nurture high-potential ventures across various sectors.

Anthro Ventures is an early-stage venture capital firm focused on transforming healthcare and life sciences. The fund aims to improve patient outcomes while simultaneously reducing healthcare costs by investing in innovative, cutting-edge technologies. Anthro Ventures has made notable investments in companies such as Hannah Life Technologies and Ride Health, which align with their goal of addressing unmet clinical needs. Their investment strategy targets early-stage companies—primarily in pre-seed, seed, and Series A rounds. They focus on startups developing impactful medical devices, diagnostics, and digital health solutions. Geographically, their investments span both the U.S. and international markets, including regions like Singapore. Led by managing director Martin Akhavan, Anthro Ventures offers a hands-on approach, guiding their portfolio companies through growth and market dynamics. They tend to favor companies that present a clear path to scalability and that align with their mission of "humanizing healthcare." Startups looking to partner with Anthro should demonstrate both technological innovation and a strong potential to drive down healthcare costs.

Anzu Partners is a venture capital firm founded in 2014, focusing on breakthrough industrial and life sciences technologies. Headquartered in Washington, D.C., with additional offices in Boston, San Diego, and Tampa, the firm manages over $1 billion in strategic assets across various funds and investment strategies. Anzu Partners has a robust portfolio of around 40 companies, including notable investments in e-Zinc, Framework, EnCharge, AM Batteries, and Arduino. The firm has also achieved significant exits, such as NUBURU and Ai-Media, highlighting its capability to support companies from early stages through to successful public offerings or acquisitions. Anzu specializes in three primary investment solutions: venture capital investments, debt and revenue-based investments, and Special Purpose Acquisition Companies (SPACs). The firm provides not just capital but also deep expertise in business development, market positioning, global connectivity, and operations, helping to drive the commercial success of its portfolio companies. The leadership team at Anzu Partners includes experienced professionals like Managing Partners David Michael, David Seldin, and Whitney Haring-Smith, who bring decades of combined experience in global investments and consultancy. This expertise is further supported by a dedicated team of technical and operational professionals.

Apax Partners is a leading global private equity advisory firm with a focus on inspiring growth and transforming businesses. Founded nearly 50 years ago, Apax has raised and advised over 30 funds, managing more than $77 billion in aggregate capital. The firm primarily invests in four sectors: Tech, Services, Healthcare, and Internet/Consumer. Apax operates several strategic funds, including Apax Global Buyout, which focuses on transformative growth in key sectors, and Apax Digital Growth, aimed at accelerating tech companies. Additionally, Apax Global Impact targets companies that deliver tangible societal and environmental benefits, while Apax Mid-Market Israel leverages local expertise to support growth in Israeli businesses. The firm also has Apax Credit and Apax Listed Private Equity strategies to provide a flexible investment approach across the capital structure​. Notable investments include Auto Trader Group, GlobalLogic, and Cole Haan, among others. Apax leverages its deep sector expertise and global network to drive operational excellence and digital transformation within its portfolio companies. The firm’s extensive experience and strategic focus have made it a prominent player in private equity globally, with offices in major financial hubs including London, New York, Hong Kong, and Tel Aviv​.

Aperture Venture Capital (Aperture VC) is a venture capital firm founded in 2021, based in Radnor, Pennsylvania. The firm focuses on investing in early-stage companies, particularly those led by diverse founders who are building the future of fintech and enterprise software. Aperture VC's mission is to redefine the venture capital landscape by supporting the "Multicultural Mainstream," which includes Black, Latinx, and female entrepreneurs. Aperture VC’s unique approach involves its Diversity Investing API℠, a platform designed to connect corporate partners with diverse talent and market innovations. This platform also provides portfolio companies with critical operating resources to help them scale. The firm believes that by investing in diverse founders, they can unlock untapped potential and drive significant impact in the venture capital ecosystem. Aperture VC has quickly gained recognition in the industry, attracting investments from major corporations like PayPal, which have recognized the value of supporting diverse founders. The firm is committed to fostering an inclusive ecosystem where diverse entrepreneurs can thrive and achieve successful exits.

APEX Ventures is a venture capital firm based in Vienna, Austria, specializing in deep tech and medical technology startups. Founded in 2016, APEX Ventures invests in early-stage companies across Europe, with a focus on innovations in AI, quantum computing, automation, robotics, computer vision, space technology, and medical technology. The firm emphasizes backing startups with unique, defensible technologies that have the potential to disrupt and transform their respective industries​. In 2023, APEX Ventures partnered with Amadeus Capital Partners to launch the Amadeus APEX Technology Fund, which aims to raise €80 million to support deep tech startups primarily in the DACH region (Germany, Austria, and Switzerland). This fund focuses on seed and Series A investments, typically ranging from €1 million to €1.5 million. The partnership combines APEX’s local expertise and network with Amadeus’ extensive global experience in venture capital. APEX Ventures has a diverse portfolio, including companies like contextflow, ImageBiopsy Lab, and Mobius Labs. The firm is known for providing not just capital but also strategic support, leveraging their deep tech expertise and strong networks to help startups scale and succeed​.

Apollo Projects, spearheaded by the Altman brothers—Sam, Jack, and Max—is a venture capital firm that specializes in funding transformative, early-stage companies. With a focus on "moonshots," Apollo targets startups with the potential to disrupt industries and create significant societal impact. Their portfolio boasts notable investments like KoBold Metals, which uses artificial intelligence for mineral exploration, and Glydways, a revolutionary transportation company. Apollo Projects is particularly active in sectors such as AI, renewable energy, and advanced biotechnology, where innovation can drive profound change. The firm typically leads funding rounds, writing substantial checks to support the ambitious goals of its portfolio companies. Apollo's investment strategy is centered around identifying and nurturing startups that are not only innovative but also have a clear vision for large-scale impact. They are especially interested in companies that challenge the status quo and push the boundaries of technology and industry norms. With a seasoned team led by the Altman brothers—each bringing a wealth of experience from their diverse backgrounds—Apollo Projects offers more than just capital. They provide strategic guidance and a deep network of industry connections, making them an invaluable partner for startups aiming to scale quickly and effectively. Entrepreneurs with bold, disruptive ideas often find Apollo Projects to be an ideal ally in their journey to bring groundbreaking technologies to market. This combination of financial backing, expertise, and a shared vision for the future positions Apollo Projects as a pivotal force in the venture capital landscape.

Apollo Health Ventures is a transatlantic venture capital firm with offices in Berlin and Boston, focusing on biotechnology and health tech ventures aimed at extending human healthspan. Established in 2016, Apollo specializes in seed and early-stage investments, particularly in companies that target aging-related diseases and conditions. Their investments focus on developing technologies and therapeutics that address the root causes of aging, helping to maintain cellular health, reduce chronic inflammation, and strengthen the immune system. In 2021, Apollo closed its second fund at $180 million, supported by both existing and new investors. This fund is designed to build and invest in data-driven companies developing breakthrough treatments for age-related diseases. Apollo has co-founded several pioneering companies, including Samsara Therapeutics, which develops autophagy-enhancing molecules, and Aeovian Pharmaceuticals, which focuses on therapeutics to extend healthspan. The firm is led by a team of experienced biotech investors and entrepreneurs, including co-founder Nils Regge, whose ventures have raised over $1 billion in capital. The team also includes Dr. Jens Eckstein, a seasoned venture capitalist with a history of successful biotech investments, and Dr. Marianne Mertens, who brings extensive experience from life sciences and venture investing. With its unique focus on longevity and aging-related innovation, Apollo Health Ventures is at the forefront of biotech ventures aiming to transform healthcare.

Apple Tree Partners (ATP) is a distinguished venture capital firm focused on life sciences, founded in 1999 by Dr. Seth Harrison. With offices in New York, San Francisco, and Cambridge, ATP has committed $2.9 billion in capital, making it one of the key players in biotech venture investing. The firm’s approach is unique in that it both creates and invests in companies, often starting from early-stage scientific ideas or asset spinouts from other companies. ATP provides flexible capital and strategic support to foster the development of science-driven enterprises. The firm is involved in every stage of a company’s life cycle, from seed investments to IPO and beyond. Notably, ATP has been instrumental in launching over 30 life sciences companies, of which 19 have gone public or been acquired. Some successful portfolio companies include Chinook Therapeutics, Akero Therapeutics, and Stoke Therapeutics​. In addition to financial backing, ATP brings operational expertise to its portfolio companies, helping them navigate clinical trials, regulatory processes, and market entry strategies. The firm has pioneered advancements in fields such as oncology, metabolic diseases, and inflammatory disorders, combining deep scientific understanding with entrepreneurial rigor. ATP’s investments, including its recent creation of Deep Apple Therapeutics, exemplify its commitment to using cutting-edge technologies like AI and machine learning to accelerate drug discovery and deliver life-changing therapies.

Apposite Capital is a London-based venture capital firm specializing in the healthcare sector. Founded in 2006, the firm focuses on investing in innovative healthcare companies across the UK and Europe. Apposite Capital provides a mix of venture, development, and growth financing, along with buyout capital, primarily targeting companies that can significantly impact healthcare through improved services and technologies. Their investment strategy emphasizes supporting companies with scalable business models and strong growth potential. Apposite Capital has a track record of successful investments in healthcare services, medical devices, diagnostics, and digital health. The firm typically takes an active role in its portfolio companies, providing strategic guidance and leveraging its extensive network within the healthcare industry to drive growth and innovation. Apposite Capital's team brings a combination of operational, scientific, and financial expertise, allowing them to deeply understand and support the unique needs of healthcare businesses. They also focus on promoting best practices in environmental, social, and governance (ESG) and are committed to making a positive impact through their investments. Recent notable investments include companies like NIMGenetics, HCML, and Emblation, showcasing their commitment to advancing healthcare solutions and improving patient outcomes​.

Aqua-Spark, based in the Netherlands, is a global investment fund dedicated to sustainable aquaculture. Founded in 2013 by Mike Velings and Amy Novogratz, the fund aims to transform the aquaculture industry by promoting environmental and social sustainability alongside financial returns. Aqua-Spark's mission is to make the production of aquatic life such as fish, shellfish, and plants safe, accessible, and environmentally friendly. The fund manages around $450 million in assets and has invested in 24 companies across the aquaculture value chain, aiming to expand its portfolio to 50-60 companies. Some notable investments include eFishery, an Indonesian aquaculture tech startup, Calysta, a biotech company producing sustainable feed ingredients, and Wanda Fish, which is developing cultivated bluefin tuna. Aqua-Spark focuses on early-stage investments, typically at the Series A stage, and supports companies through to maturity. Their investments are chosen for their potential to generate significant environmental and social impacts while delivering solid financial returns. The fund has a diverse investor base of around 300 investors from over 25 countries.

Aquarius Equity is a UK-based venture capital firm with a strong focus on early-stage investments in high-growth companies, particularly those located in the North of England. The firm, established to bridge the venture capital gap in this region, is dedicated to supporting innovative startups that have the potential to scale significantly. Their latest fund, the Aquarius Origin Fund, targets investments of up to £750,000, focusing on sectors like biotechnology, life sciences, and technology. Aquarius Equity's investment strategy emphasizes scalability and sustainability, with a particular interest in companies that align with the UN Sustainable Development Goals. They seek out companies with proven business models and significant growth potential, especially those that have already secured investment from industry-recognized investors. The firm also encourages investments from private individuals through Self Invested Personal Pension (SIPP) schemes, allowing them to invest in early-stage companies traditionally dominated by institutional funds. Aquarius Equity is not just a financial backer but also an active partner, providing strategic support to help startups achieve their growth ambitions. The firm’s commitment to innovation and sustainability positions it as a key player in the venture capital landscape, particularly in the UK’s underserved Northern regions.

Aquilo Capital Management is a biotech-focused investment firm based in San Francisco, established in 2010. The firm specializes in funding drug development companies that utilize cutting-edge science to address urgent medical needs. Aquilo’s approach is rooted in deep sector expertise and a disciplined, value-oriented investment strategy. They focus on identifying biotech companies with the potential to create transformative therapeutics that can significantly impact healthcare and society. The firm’s investment strategy is heavily concentrated in life sciences, targeting innovative drug discovery and development projects. They aim to balance risk with high potential returns, favoring companies that are on the cusp of delivering paradigm-shifting treatments. Aquilo employs both a long-only and hedged investment strategy, giving them flexibility and resilience in volatile markets. Notable investments include pioneering biotech firms like Arrowhead Pharmaceuticals and Regenxbio. Aquilo Capital is led by founder and CIO Marc Schneidman, who brings over 20 years of experience in the biotech investment space. The firm takes a global perspective, with a keen interest in leveraging opportunities in both the U.S. and Europe. They are known for supporting early-stage ventures and maintaining strong relationships with the scientific and biotech communities. Aquilo’s mission is to bridge the gap between groundbreaking science and successful commercial application, delivering both societal benefits and strong returns for investors.

Aravis is a private equity firm based in Zurich, Switzerland, founded in 2001 by Jean-Philippe Tripet. The firm focuses on high-tech growth investments, primarily in the biotech, creative and digital, and industrial high-tech sectors. Aravis has sponsored multiple fund vintages and has deployed over USD 400 million across four funds. Aravis Growth I LP, their latest initiative, targets investments in established, innovative Swiss and European companies with significant growth potential. This fund aims to fill the gap in growth capital in the region by offering strategic advice, access to networks, and capital to accelerate companies through their growth phases​. The team at Aravis is composed of experienced professionals from various backgrounds, including finance, industry, and technology, providing a wealth of knowledge and expertise to support their portfolio companies. Their investment approach also integrates ESG criteria, aligning with several UN Sustainable Development Goals (SDGs).

ARAX Capital Partners, founded in 2007 and based in Vienna, Austria, is a venture capital firm that focuses on early-stage investments across the life sciences and technology sectors. They are particularly invested in Austrian ventures, targeting young, innovative companies, especially those with patentable technology. ARAX is committed to fostering the growth of startups in these fields by providing significant strategic and financial support. The firm's notable investments include Calyxha Biotechnologies, EveliQure Biotechnologies, and Panoptes Pharma, showcasing their emphasis on biotech and life sciences. Additionally, they have invested in technology companies like The MoonVision and crystalsol, a renewable energy company​​. ARAX Capital Partners generally participates in funding rounds ranging from $1 million to $9 million and has made 41 investments to date. They typically lead rounds, indicating their active role in shaping the growth trajectories of their portfolio companies​​. The team at ARAX is led by experienced partners such as Christian Tiringer, Beatrix Schuberth, and Thomas Cimbal, who bring extensive expertise in venture capital and entrepreneurship to the firm​​. This leadership helps ARAX maintain a strong network and high-quality deal flow, positioning them as a key player in Austria’s venture capital landscape. For startups, ARAX Capital Partners is a valuable partner, particularly for those in the early stages of development, looking for both capital and strategic guidance to scale their innovative solutions in the biotech and technology sectors​.

Arboretum Ventures, headquartered in Ann Arbor, Michigan, is a prominent venture capital firm specializing in the healthcare sector. Founded in 2002 by Jan Garfinkle and Tim Petersen, the firm manages $1 billion across six funds. Arboretum Ventures focuses on capital-efficient investment opportunities in medical devices, life science tools, diagnostics, tech-enabled care delivery, and pharma adjacencies​. The firm has a strong commitment to investing in under-ventured geographies, particularly in the Midwest. Their portfolio includes a variety of innovative companies such as NeuMoDx, which was acquired by QIAGEN, and Fifth Eye, known for its early warning system for patient care​. Arboretum's investment strategy emphasizes supporting startups that aim to reduce healthcare costs while improving patient outcomes. They are active partners, providing strategic guidance and leveraging their extensive network to help portfolio companies succeed. The team includes managing partners Jan Garfinkle, Dr. Tom Shehab, Dan Kidle, and other key members like Paul McCreadie and Marcy Marshall. Overall, Arboretum Ventures stands out for its proactive involvement with entrepreneurs and its focus on transformative healthcare solutions that address significant industry challenges​,

Arc Ventures is a New York-based venture capital firm that connects founders with a global network of funds, advisors, and industry experts. Focused on fostering innovation, Arc Ventures operates as the venture arm of a single family office, originally part of Arc Group Holdings. The firm emphasizes long-term partnerships and operates across diverse geographies, including the U.S., Israel, and Europe, with plans to expand into Asia. Founded in 2019, Arc Ventures invests in both startups and venture funds, supporting entrepreneurs in sectors like fintech, health tech, digital media, and autonomous driving. Notable companies in their portfolio include Arbe Robotics, Alpha Tau, and Allure Security. The firm leverages its extensive network to introduce founders to potential customers, funding sources, and strategic partners, helping them scale quickly. The firm prides itself on a unique approach that blends data-driven insights with human connections, ensuring that promising ventures receive both financial backing and the mentorship needed to thrive.

Arch Venture Partners is a powerhouse in venture capital, specializing in early-stage investments in life sciences and technology. With a notable portfolio that includes industry leaders like Grail, Illumina, and Denali Therapeutics, Arch focuses on groundbreaking innovations that transform healthcare and biotech. They have a strong geographic footprint in the United States, with significant investments also in China and the UK. Their investment strategy centers on nurturing disruptive technologies with high-impact potential. Arch Venture Partners typically leads investment rounds, deploying substantial capital to accelerate growth, evidenced by their recent $2.975 billion Fund XII. The firm prioritizes deep scientific expertise and collaborates closely with founders to guide long-term strategic development. Average check sizes vary, but their robust funding capabilities mean they often make sizable commitments. Founded in 1986, Arch is driven by a team of seasoned professionals, including co-founder Robert Nelsen, who has been instrumental in the success of numerous billion-dollar companies. The firm values direct and collaborative approaches from startups, emphasizing the importance of innovative ideas backed by solid research. Overall, Arch Venture Partners stands out for its dedication to pioneering science and technology, its active role in funding and strategy, and its impressive track record of high-profile successes.

Archetype is an early-stage venture capital firm that focuses on accelerating the decentralized future, primarily backing startups in the Web3 and cryptocurrency space. Founded in 2021 and based in New York, Archetype is led by founder Ash Egan and a team of experienced professionals from the crypto, investing, and engineering worlds. The firm invests in seed-stage companies, with check sizes typically ranging from $1M to $3M. They also lead many of their funding rounds. Archetype is known for backing founders who are disrupting traditional industries by creating entirely new markets within the decentralized economy. The firm's portfolio includes standout names like Alchemy, Socket, and Mona, all of which focus on cutting-edge technologies in crypto infrastructure, blockchain development, and decentralized applications. Archetype’s investment philosophy is centered on supporting founders with deep technical expertise and a vision for decentralization. They are highly active in the U.S., with a particular focus on startups that bring innovation to financial services, infrastructure, and software development. The firm also provides strategic guidance, leveraging its team’s extensive network within the crypto ecosystem to help startups grow from concept to market-ready products. By combining their expertise in both technology and operations, Archetype positions itself as a critical partner for crypto founders looking to build and scale innovative projects in the decentralized world.

Archimed Group, founded in 2014 and headquartered in Lyon, France, is a leading private equity firm specializing in the healthcare sector. The firm manages around €8 billion in assets and is focused on investing in small to midsize companies across seven key healthcare sectors, including Biopharma, MedTech, and Healthcare IT. Archimed’s strategy involves acquiring majority stakes in companies and working closely with them to accelerate growth, drive innovation, and expand internationally. Archimed has a strong track record, with its funds consistently ranking in the top decile for performance. The firm’s latest fund, MED Platform II, closed at €3.5 billion in 2023, making it the largest healthcare-only private equity fund raised by a European-based firm. This fund is primarily focused on mid-cap companies in Europe and North America, aiming to support healthcare leaders in scaling their operations through strategic acquisitions and capacity expansions. Archimed’s commitment to impact investing is evident through its alignment with sustainable development goals and its EURÊKA Foundation, which supports healthcare-related charitable initiatives. The firm’s unique blend of financial, medical, and operational expertise positions it as a key player in the global healthcare investment landscape.

Aleph VC, founded in 2013 and based in Tel Aviv, specializes in early-stage investments, primarily partnering with Israeli entrepreneurs. With $850 million under management, Aleph focuses on building meaningful companies and impactful global brands across various sectors, including fintech, digital health, cybersecurity, AI, and machine learning. Notable investments by Aleph include Lemonade, a full-stack global insurance company, and Melio, which provides digital payment tools for small businesses. Other prominent portfolio companies include Nexar, a dashcam and edge-AI platform for better driving, and Freightos, a digital freight marketplace. The firm has also seen significant exits, such as the acquisition of Raftt and the public offering of Freightos​. Aleph typically invests between $2 million and $12 million in seed and pre-seed stages, focusing on innovative companies poised for global expansion. The team, led by co-founders Michael Eisenberg and Eden Shochat, leverages their extensive network and expertise to provide strategic guidance and access to global markets, aiming to create long-term value for their portfolio companies.

Arix Bioscience is a global venture capital firm based in London, specializing in biotechnology investments. Founded in 2016, Arix focuses on backing early-stage companies that are developing breakthrough treatments and technologies in the life sciences sector. Their investment strategy targets ventures from late pre-clinical to clinical stages, emphasizing a diversified portfolio to mitigate risks inherent in biotech investments​. The firm has built a robust portfolio that includes companies like Autolus, a developer of CAR-T cell therapies for cancer, and Disc Medicine, which focuses on treatments for hematologic diseases. Arix has also been involved in significant financing rounds, such as the $50 million Series B for Evommune and Ensoma, highlighting their role in advancing innovative biotech startups. Arix operates a permanent capital model, allowing it to support its portfolio companies through market fluctuations without being bound by strict exit timelines. This approach enables them to provide sustained support to their investments, which is critical in the high-risk, high-reward biotech sector.

Arkitekt Ventures is a New York-based venture capital firm focused on advancing human health through early-stage investments. Their portfolio emphasizes innovative healthcare solutions, including digital health platforms, biotech, and frontier technologies like neurotech, AI, and bioengineering. Notable recent investments include Sollis Health, Nanite, and Mural Health, with check sizes ranging from $3M to $15M. Arkitekt primarily invests in the U.S. but has also backed companies in the UK, maintaining a sector focus in healthtech, medical devices, and life sciences. Their strategy centers on pre-seed to Series A stages, preferring startups with groundbreaking approaches to healthcare delivery and precision medicine. They rarely lead rounds but frequently co-invest with prominent partners like Bessemer Venture Partners and Torch Capital. Led by managing director Enke Bashllari and partner Pavan Choksi, Arkitekt Ventures values long-term partnerships and tends to back visionary founders who are leveraging cutting-edge science. Their team prefers a data-driven, relationship-building approach, and startups seeking funding should ideally present transformative technologies with strong early traction.

Artesian Investments, founded in 2004 by Jeremy Colless, Matthew Clunies-Ross, and John McCartney, is a global alternative investment management firm specializing in venture capital, public and private debt, and impact investment strategies. Based in Sydney, the firm has expanded its reach with offices in Melbourne, Adelaide, Shanghai, Jakarta, Singapore, London, and New York​​. Artesian's notable investments include Instaclustr, PouchNATION, and Regrow Ag. They are particularly active in the Asia-Pacific region, managing over $1.22 billion in assets and boasting more than 600 startup investments​ (Artesian)​. Their investment strategy focuses on early-stage ventures across various sectors, including technology, agrifood, medtech, and AI. Artesian also offers a unique "Venture Capital as a Service" (VCaaS) platform, providing customized investment solutions to corporations, government, and family offices​. The firm places a strong emphasis on ESG (Environmental, Social, and Governance) criteria and impact investing, aiming to deliver sustainable returns while addressing critical global challenges. Artesian is a certified B Corp, underscoring their commitment to positive social and environmental impact. Key team members include Jeremy Colless (CEO), Matthew Clunies-Ross (CIO), and Luke Fay (Partner, Australian Venture Capital). Their diversified team spans multiple continents, bringing extensive expertise and a global perspective to their investment activities

Artiman Ventures, founded in 2001, is a venture capital firm based in Silicon Valley with an additional office in Bangalore. The firm specializes in early-stage investments and adopts a "white space" investment strategy, focusing on sectors with little to no existing competition, thereby seeking to create or disrupt multi-billion dollar markets. Artiman is sector-agnostic and invests across a diverse range of industries including technology, medtech, and communications. Notable investments in Artiman's portfolio include companies like Virsec, which focuses on application security, and Visby Medical, which is revolutionizing disease diagnostics. Other significant investments include ApplyBoard, an AI-enabled marketplace for international students, and CellMax Life, a precision cancer blood-testing company. Geographically, Artiman primarily invests in companies based in the U.S. and India, leveraging its cross-border presence to help startups scale globally. Their investment strategy involves being the first institutional capital, often at the concept phase, and working closely with entrepreneurs to drive strategy, market definition, and execution​. The leadership team at Artiman includes experienced partners like Yatin Mundkur, Amit Shah, and Ajit Singh, who bring deep expertise in technology and life sciences investments. Founder Eric Benhamou, known for his tenure as CEO of 3Com and Palm, leads the team with a strong background in growing and managing tech companies.

Artis Ventures (AV) is a pioneering venture capital fund that specializes in the convergence of technology and biology, a field they have coined "TechBio." This innovative approach leverages advancements in AI, machine learning, and data science to transform healthcare and life sciences, aiming for scalable global impact. Notable investments include Rad AI, which uses artificial intelligence to enhance radiology, and Precision Neuroscience, a leader in neuroplasticity-promoting therapeutics. AV primarily focuses on data-driven life sciences companies that address critical healthcare challenges and are capable of achieving broad, scalable impact. Their industry scope spans oncology, cardiopulmonary, neurology, and beyond, often targeting companies with strong engineering and data science foundations. Geographically, AV invests globally, supporting founders from over 30 countries to foster innovations that can be scaled worldwide. The fund's strategy is centered around investing in early-stage startups with robust technical foundations and significant potential for positive health outcomes. They prefer to lead investment rounds and actively engage with their portfolio companies, offering not just capital but also strategic support and access to a vast network of industry experts. AV's investment team includes prominent figures like Laura Bordewieck Rippy and Luke Antal, who bring extensive experience and a strong track record in venture capital and entrepreneurial support. They are based in San Francisco, a hub for tech and biotech innovation. For startups looking to engage with AV, it's crucial to demonstrate a clear vision for scalable health solutions backed by solid technical expertise. AV values a data-driven approach and is keen on companies that can show potential for significant, measurable impact on global health outcomes.

Asahi Kasei Ventures is the corporate venture capital arm of Asahi Kasei, a diversified Japanese conglomerate with major operations in materials, homes, and healthcare. The venture fund focuses on early-stage investments globally, with a particular emphasis on startups that align with Asahi Kasei's strategic interests, such as advanced materials, healthcare innovations, and sustainability technologies. The fund is particularly active in sectors like hydrogen energy, carbon management, and bio-based chemicals, supporting startups that contribute to environmental sustainability. Asahi Kasei Ventures operates from key locations including Tokyo, Düsseldorf, and Shanghai, ensuring a broad geographic reach to identify and support innovative technologies worldwide. Asahi Kasei Ventures not only provides financial support but also leverages the vast resources and expertise of the broader Asahi Kasei Group, which has over 287 subsidiaries and a significant global footprint. This enables startups in their portfolio to benefit from deep industry knowledge, extensive networks, and strategic partnerships to accelerate their growth and impact.

Ascension Ventures is a strategic healthcare-focused venture capital firm based in St. Louis, Missouri. Launched in 2001 by Ascension, it manages over $1 billion in assets across five funds. The firm strategically invests in early to late-stage companies within healthcare services, health technology, and medical devices. Its unique approach connects more than 450 healthcare providers, creating an ecosystem that enables startups to directly engage with health system executives, driving solutions that address complex healthcare challenges. Ascension Ventures’ portfolio includes companies like Olive (an AI platform for healthcare administration), EBR Systems, and GetWellNetwork, reflecting its emphasis on technology that enhances clinical outcomes, patient experience, and operational efficiency. The firm typically invests between Series A and B rounds, with capital sizes ranging from $10 to $20 million per company, often seeking board seats or observer rights to guide their portfolio firms. The firm is distinguished by its close ties to 13 major health systems, which represent a network of over 580,000 healthcare professionals. This strategic positioning allows Ascension Ventures not only to provide funding but also to facilitate partnerships and scale innovations that improve healthcare delivery across the United States.

Aspect Ventures, founded in 2014 by Jennifer Fonstad and Theresia Gouw, is a leading venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments, primarily in Series A rounds, across various sectors including cybersecurity, fintech, digital health, and enterprise software. Notable investments include Gusto, a cloud-based HR management platform; Chime, a digital bank; and Exabeam, a cybersecurity company. Aspect Ventures has had several successful exits such as Forescout Technologies, Imperva, and Trulia.

Astanor Ventures, founded in 2017 by Eric Archambeau and George Coelho, is a Brussels-based venture capital firm specializing in sustainable agrifood technologies. The firm focuses on investing in early-stage, mission-driven companies that address significant social or environmental issues within the agrifood value chain. This includes sectors like regenerative agriculture, bioeconomy, and climate-positive solutions. Astanor recently closed its second venture fund at €360 million, bringing its total assets under management to €800 million. This fund will support innovative solutions aimed at transforming the global food system to be more sustainable and resilient​. The firm boasts an extensive network of entrepreneurs, experts, scientists, and policymakers, which helps identify and nurture groundbreaking technologies. Notable investments include companies that advance autonomous electric agricultural machinery, high-functioning proteins, and genomic sequencing for sustainable food production.

Astarc Ventures, established in 2015, is the corporate venture arm of Astarc Group based in Mumbai, India. The fund focuses on early-stage investments in innovative technology companies across various sectors, including fintech, healthtech, logistics, AI/ML, and e-commerce. Notably, Astarc Ventures invests globally, with a presence in markets like India, Israel, the United States, and the United Kingdom. The firm typically supports entrepreneurs whose ventures align with Astarc Group's strategic interests and disruptive technologies. With over 60 investments, Astarc Ventures has backed companies such as Rooter, Purple Style Labs, Jai Kisan, and Dataloop. These investments span diverse industries from AI-driven solutions to consumer marketplaces and climate-tech. The firm is also known for its exits, including Liv.ai, which was acquired by Flipkart in 2018. Led by Executive Director Salil Musale and an experienced team, Astarc Ventures leverages deep operational expertise to help portfolio companies scale. The team takes an active role in guiding startups, offering both strategic advice and operational support, especially in emerging sectors.

Aster Capital, established in 2000 and based in Paris, is a venture capital firm specializing in Climate Tech investments. The firm focuses on sectors such as energy, mobility, and industry, supporting startups at various stages of development. Aster Capital manages around €500 million in assets and operates globally with offices in Paris, San Francisco, and Tel Aviv. Key investments by Aster include companies like ekWateur, an energy supplier accelerating the energy transition; Betterway, a pioneer in employee mobility solutions; and Iceotope, specializing in liquid cooling technologies for data centers. These investments reflect Aster’s commitment to supporting innovative solutions that contribute to carbon neutrality. Aster recently raised €240 million to invest in energy transition and future mobility projects, underscoring their dedication to driving significant environmental impact through technology. The firm’s strategy involves not only financial investment but also providing extensive support through their "Business Hub" approach, which facilitates business opportunities and partnerships for their portfolio companies​.

AstraZeneca is a leading global biopharmaceutical company with a strong focus on oncology, biopharmaceuticals, and rare diseases. They are committed to discovering, developing, and delivering innovative medicines that transform the lives of patients worldwide. AstraZeneca's oncology portfolio is particularly noteworthy, with a significant emphasis on creating groundbreaking cancer treatments. Their strategy includes leveraging various scientific platforms such as antibody-drug conjugates (ADCs), radioconjugates, and T cell engagers. Recent high-profile deals include collaborations with Daiichi Sankyo for ADCs and the acquisition of Neogene Therapeutics to enhance their T cell receptor therapy capabilities​​. In addition to oncology, AstraZeneca has a robust pipeline in biopharmaceuticals aimed at addressing chronic diseases and enhancing long-term health outcomes. They are also advancing treatments for rare diseases, expanding their reach globally to ensure broader access to their innovative therapies​​. AstraZeneca's business development approach is integral to their growth, focusing on strategic alliances and partnerships. This includes collaborations with companies like Tempus for AI-enabled precision medicine and various biotech firms to accelerate advancements in areas like epigenetics and undruggable targets​​. The company emphasizes a culture of innovation, diversity, and sustainability, aiming to make a significant impact on global health while maintaining environmental responsibility through initiatives like Ambition Zero Carbon​.

Asymmetry Ventures, based in San Francisco, is a prominent early-stage venture capital firm founded by Rob Ness. The firm focuses on investing in transformative startups that have the potential to create significant impact. They have a diverse portfolio of over 280 investments, including notable companies like BillionToOne, Foresight Mental Health, Mast Reforestation (formerly DroneSeed), and Orbit Fab. Asymmetry Ventures is known for their commitment to supporting defensible businesses, particularly in sectors such as artificial intelligence, biotechnology, and aerospace. They typically make initial investments in the range of $2 million and have been involved in notable funding rounds such as Orbit Fab's $10 million raise, which also saw participation from major aerospace players like Northrop Grumman and Lockheed Martin. The firm prides itself on identifying and backing visionary founders and innovative business models, with a strong emphasis on early-stage investments that leverage technology to create natural barriers to entry and generate recurring revenue streams. They also prioritize investments that address significant market needs with scalable solutions. For startups looking to partner with Asymmetry Ventures, demonstrating a strong leadership team and a clear path to market dominance are crucial. The firm's deep network and extensive industry experience provide valuable support and guidance to their portfolio companies, enhancing their potential for growth and success.

At One Ventures is a venture capital firm founded in 2020 by Tom Chi, a founding member of Google X. The firm is dedicated to investing in early-stage startups that are developing disruptive deep tech solutions aimed at making humanity a net positive to nature. With a strong focus on climate tech, At One Ventures has established itself as a significant player in the industry. The firm recently closed its second fund at $375 million, indicating strong investor confidence and a robust commitment to supporting climate-positive innovations. This fund follows their initial $150 million fund and aims to support startups that can dramatically reduce environmental footprints while upending established industrial economics. At One Ventures' investment portfolio includes companies across various sectors such as renewable energy, sustainable agriculture, and advanced materials. Notable investments include Noon Energy, which focuses on long-duration energy storage, and MightyFly, which is developing hybrid electric drone delivery systems. The firm's approach is hands-on, providing strategic guidance in talent acquisition, operations, marketing, IP strategy, and manufacturing. The team at At One Ventures consists of experienced professionals with backgrounds in physical sciences, engineering, manufacturing, and finance, ensuring a deep understanding of the technologies and markets they invest in. They operate globally, with a presence in San Francisco and London, and continue to seek partnerships with entrepreneurs, scientists, and investors who share their vision for a sustainable future.

Ataraxia VC is a global venture capital firm managing multiple funds, including the Social Starts and Joyance Partners funds, which focus on early-stage investments in health, happiness, and well-being. Ataraxia typically operates at the pre-seed and seed stages, with follow-on investments up to Series A. They target sectors like biotech, neuroscience, precision health, femtech, and next-gen food technologies. Their portfolio includes over 250 companies globally, with a strong focus on science-driven, transformative opportunities. The firm's strategy emphasizes investments in innovative companies that align with its vision of improving health and happiness through technology. With funds spread across the US and Europe, Ataraxia provides both capital and strategic guidance to help startups scale rapidly. They prioritize founders with groundbreaking solutions, especially in consumer tech, wellness, and sustainability-focused sectors. Key team members include Mike Edelhart, a seasoned investor with decades of experience, and Holly Jacobus, an investment partner with a focus on femtech, farmtech, and sustainable manufacturing. Ataraxia’s approach is hands-on, often providing mentorship and guidance through every stage of a startup’s journey​.